The commonest avoidable harm in the first month of a GLP-1 receptor agonist is not nausea. It is hypoglycaemia in a patient who stayed on a full-dose sulphonylurea, or on the basal insulin dose that was set at the last visit.
A GLP-1 receptor agonist lowers glucose and reduces food intake at the same time. Both push in the same direction as a sulphonylurea, and the appetite effect arrives faster than most titration schedules allow for. The patient who is eating a third less from week one is running on a dose calculated for the appetite they had in week zero. The hypoglycaemia that follows is usually blamed on the new drug, and it often ends the treatment.
Make the reduction at the same consultation as the new prescription. Halve the sulphonylurea, and where HbA1c is already below about 8%, reduce basal insulin by roughly a fifth. Then arrange a glucose review at two weeks rather than at the next routine appointment. This is consensus practice rather than a trial result - there is no effect size to quote - but it is the step most often deferred to next time, and next time is usually after the event.
- Write the reduced sulphonylurea or insulin dose on the same prescription as the GLP-1 receptor agonist.
- Ask specifically about mid-morning and pre-lunch symptoms; that is when sulphonylurea hypoglycaemia surfaces once appetite drops.
- Tell the patient to expect smaller meals, and to report sweating, tremor or confusion rather than assume it is the new drug's nausea.
- Review capillary glucose or CGM (continuous glucose monitoring) at two weeks, not at three months.
- Warn about driving, and about fasting for religious observance, during the first month.
The statistics, in plain English
There are no trial numbers behind this one, and that is worth saying plainly rather than dressing it up: it is consensus practice built on how the drugs work, not a measured effect from a randomised comparison. Treat the dose reductions as starting points to be adjusted against the glucose readings that come back at two weeks, not as fixed rules. Where a patient is already on a low sulphonylurea dose, or has a history of hypoglycaemia unawareness, stopping the sulphonylurea outright is a safer starting point than halving it.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for diabetes & endocrinology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free